John J Nemunaitis (John Nemunaitis)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 32

Top Topics

Immune Response

Squamous Cell Carcinoma

Top Venues

Future oncology (London, England)

International journal of molecular sciences

Communications medicine

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Nicole Kaplinsky, Kada Williams, Dean E Watkins, Molly Adams, Laura Stanbery, John J Nemunaitis
Regulatory role of CD39 and CD73 in tumor immunity. Future oncology (London, England) (2024)
Nicole Kaplinsky, Kada Williams, Dean E Watkins, Molly Adams, Laura Stanbery, John J Nemunaitis
Regulatory role of CD39 and CD73 in tumor immunity. Future oncology (London, England) (2024)
John J Nemunaitis, Laura Stanbery, Adam Walter, Gladice Wallraven, Alexander Nemunaitis, Staci Horvath, Ernest Bognar, Donald Rao, Steven Engle, Scott Brun, Maurizio Ghisoli, Rodney P Rocconi, Bradley J Monk, Robert L Coleman
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. Future oncology (London, England) (2024)
Nicole Kaplinsky, Kada Williams, Dean E Watkins, Molly Adams, Laura Stanbery, John J Nemunaitis
Regulatory role of CD39 and CD73 in tumor immunity. Future oncology (London, England) 20 (19) (2024)
Morgan Bailey, Susan Morand, Rachel Royfman, Leslie Lin, Aditi Singh, Laura Stanbery, Adam Walter, Danae Hamouda, John J Nemunaitis
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer. International journal of molecular sciences 25 (6) (2024)
Nicole Kaplinsky, Kada Williams, Dean E Watkins, Molly Adams, Laura Stanbery, John J Nemunaitis
Regulatory role of CD39 and CD73 in tumor immunity. Future oncology (London, England) 20 (19) (2024)
Nicole Kaplinsky, Kada Williams, Dean E Watkins, Molly Adams, Laura Stanbery, John J Nemunaitis
Regulatory role of CD39 and CD73 in tumor immunity. Future oncology (London, England) 20 (19) (2024)
Morgan Bailey, Susan Morand, Rachel Royfman, Leslie Lin, Aditi Singh, Laura Stanbery, Adam Walter, Danae Hamouda, John J Nemunaitis
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer. International journal of molecular sciences 25 (6) (2024)
Morgan Bailey, Susan Morand, Rachel Royfman, Leslie Lin, Aditi Singh, Laura Stanbery, Adam Walter, Danae Hamouda, John J Nemunaitis
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer. International journal of molecular sciences 25 (6) (2024)
John J Nemunaitis, Laura Stanbery, David Willoughby, Ernest Bognar, Scott Brun, Adam Walter, Bradley J Monk, Rodney P Rocconi, Khalil Choucair, Robert L Coleman
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response. Cancers 15 (23) (2023)
Peter Meade Anderson, Maurizio Ghisoli, Brian D Crompton, Kelly S Klega, Leonard H Wexler, Emily K Slotkin, Laura Stanbery, Luisa Manning, Gladice Wallraven, Meghan Manley, Staci Horvath, Ernest Bognar, John J Nemunaitis
Pilot Study of recurrent Ewing's Sarcoma management with Vigil/Temozolomide/Irinotecan and assessment of circulating tumor (ct) DNA. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Rodney P Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J Monk, Thomas J Herzog, Robert L Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John J Nemunaitis
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Communications medicine 2 (1) (2022)
Aung Naing, John D Powderly, John J Nemunaitis, Jason John Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for immunotherapy of cancer 10 (3) (2022)
Rodney P Rocconi, Laura Stanbery, Min Tang, Adam Walter, Bradley J Monk, Thomas J Herzog, Robert L Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John J Nemunaitis
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Communications medicine 2 (2022)
Rodney P Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J Monk, Thomas J Herzog, Robert L Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John J Nemunaitis
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Communications medicine 2 (1) (2022)
Nicholas Stimes, Laura Stanbery, Mary Albrethsen, Charu Trivedi, Danae Hamouda, Lance Dworkin, John J Nemunaitis
Small-cell breast carcinoma with response to atezolizumab: a case report. Immunotherapy (2022)
Minal Barve, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, Laura Stanbery, John J Nemunaitis
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clinical Medicine Insights. Oncology 16 (2022)
Susan Morand, Monika Devanaboyina, Hannah Staats, Laura Stanbery, John J Nemunaitis
Ovarian Cancer Immunotherapy and Personalized Medicine. International journal of molecular sciences 22 (12) (2021)
Rodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, Sharad A Ghamande, Jeffrey Elder, Leslie L DeMars, Adnan Munkarah, Phylicia A Aaron, Laura Stanbery, Gladice Wallraven, Ernest Bognar, Meghan Manley, Staci Horvath, Luisa Manning, Adam Walter, Evanthia Galanis, Thomas Herzog, Bradley J Monk, Robert L Coleman, John J Nemunaitis
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer gene therapy (2021)
Sunil Chada, Dora Wiederhold, Kerstin B Menander, Beatha Sellman, Max Talbott, John J Nemunaitis, Hyo Min Ahn, Bo-Kyeong Jung, Chae-Ok Yun, Robert E Sobol
Tumor suppressor immune gene therapy to reverse immunotherapy resistance. Cancer gene therapy (2021)
Rachel Royfman, Emma Whiteley, Olivia Noe, Susan Morand, Justin Creeden, Laura Stanbery, Danae Hamouda, John J Nemunaitis
BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer. Future oncology (London, England) 17 (21) (2021)
Justin Fortune Creeden, Nisha S Nanavaty, Katelyn R Einloth, Cassidy E Gillman, Laura Stanbery, Danae M Hamouda, Lance Dworkin, John J Nemunaitis
Homologous recombination proficiency in ovarian and breast cancer patients. BMC cancer 21 (1) (2021)
Elyssa Sliheet, Molly Robinson, Susan Morand, Khalil Choucair, David Willoughby, Laura Stanbery, Phylicia A Aaron, Ernest Bognar, John J Nemunaitis
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. Cancer gene therapy (2021)
Michael S Gordon, John J Nemunaitis, Minal Barve, Zev A Wainberg, Erika P Hamilton, Ramesh K Ramanathan, George W Sledge, Huibin Yue, Susan E Morgan-Lappe, Martha Blaney, Sreeneeranj Kasichayanula, Monica Motwani, Lan Wang, Louie Naumovski, John H Strickler
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Molecular cancer therapeutics 20 (10) (2021)
Daniel J Craig, Nisha S Nanavaty, Monika Devanaboyina, Laura Stanbery, Danae Hamouda, Gerald Edelman, Lance Dworkin, John J Nemunaitis
The abscopal effect of radiation therapy. Future oncology (London, England) 17 (13) (2021)
Matthew H Taylor, Courtney B Betts, Lauren Maloney, Eric Nadler, Alain Patrick Algazi, Michael J Guarino, John J Nemunaitis, Antonio Jimeno, Priti Patel, Veerendra Munugalavadla, Lin Tao, Douglas Adkins, Jerome H Goldschmidt, Ezra E W Cohen, Lisa M Coussens
Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Christine Cassidy, Danielle Dever, Laura Stanbery, Gerald Edelman, Lance Dworkin, John J Nemunaitis
FDA efficiency for approval process of COVID-19 therapeutics. Infectious agents and cancer 15 (1) (2020)
Mary Albrethsen, Justin Creeden, Susan Morand, Joseph DeBiase, Brittany Berry, Laura Stanbery, Gerald Edelman, John J Nemunaitis
Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. Immunotherapy 12 (14) (2020)
Susan Morand, Laura Stanbery, Adam Walter, Rodney P Rocconi, John J Nemunaitis
BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target. JNCI cancer spectrum 4 (6) (2020)
Daniel J Craig, Justin Fortune Creeden, Katelyn R Einloth, Cassidy E Gillman, Laura Stanbery, Danae Hamouda, Gerald Edelman, Lance Dworkin, John J Nemunaitis
Resident Memory T Cells and Their Effect on Cancer. Vaccines 8 (4) (2020)
Donald D Rao, Xiuquan Luo, Zhaohui Wang, Christopher M Jay, Francis C Brunicardi, William A Maltese, Luisa Manning, Neil Senzer, John J Nemunaitis
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. PloS one 13 (5) (2018)
Luisa Manning, John J Nemunaitis
Harnessing the immune response to target tumors. F1000Research 6 (2017)